Cardiol Therapeutics Inc. current report, Q1 FY2022

Cardiol Therapeutics Inc. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K was filed by Cardiol Therapeutics Inc., a foreign private issuer, for the month of March 2022. The report was submitted on March 15, 2022, and includes a news release regarding corporate governance updates.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate announcement rather than financial performance data.

Material Changes

The primary material change disclosed is the appointment of Jennifer M. Chao to the Company's Board of Directors, as detailed in the accompanying news release (Exhibit 99.1).

Guidance, Outlook, and Risks

The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the board appointment.

Key Facts for Investor Verification

  • Verify the background and qualifications of the newly appointed Board member, Jennifer M. Chao.
  • Confirm the effective date of the board appointment.
  • Review the full text of the news release (Exhibit 99.1) for any additional context regarding the appointment.